3 completed, 3 recruiting, 2 unknown. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 3, Recruiting 3, Unknown 2 |
Follow Type2diabetes: new trials by email Literature Review of Type2diabetes trials Research Report on Type2diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh Omarigliptin, Sulphonylureas, Metformin - Type2diabetes | Phase 4 | Unknown | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | 938 | 2024-09-01 | 2024-07-16 |
| DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes DW6012(Dasidiem tab. 10/100mg) - Type2diabetes | Phase 4 | Recruiting | Dong Wha Pharmaceutical Co. Ltd. | 196 | 2024-05-28 | 2025-03-17 |
| A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes Dorzagliatin tablets - Type2diabetes | Phase 4 | Completed | Hua Medicine Limited | 2024 | 2024-01-17 | 2026-07-10 |
| SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes Dapagliflozin (Forxiga®), Placebo matching Dapaglifolzin, Lifestyle Intervention - Type2diabetes, PreDiabetes | Phase 4 | Recruiting | University Hospital Tuebingen | 170 | 2023-10-26 | 2026-09-15 |
| Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD Empagliflozin 10 MG, Pioglitazone 15mg, Metformin - Non-Alcoholic Fatty Liver Disease, Type2diabetes | Phase 4 | Unknown | Jinnah Postgraduate Medical Centre | 240 | 2023-10-01 | 2023-07-12 |
| Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM Henagliflozin, Continuous Subcutaneous Insulin Infusion - Type2diabetes | Phase 4 | Completed | First Affiliated Hospital of Guangxi Medical University | 210 | 2023-03-01 | 2025-03-12 |
| PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes SGLT2 inhibitor, GLP-1 receptor agonist - Type2Diabetes, ASCVD | Phase 4 | Recruiting | Brigham and Women's Hospital | 6000 | 2022-09-26 | 2026-04-13 |
| Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes Dapagliflozin, Glargine - Type2diabetes, Coronary Artery Disease | Phase 4 | Completed | Medanta, The Medicity, India | 250 | 2022-07-29 | 2023-10-19 |
Diabetes Mellitus, Type 2 (2) · Coronary Artery Disease (1) · Non-alcoholic Fatty Liver Disease (1) · Prediabetic State (1) · Renal Insufficiency (1)
Diabetes Mellitus (3) · Endocrine System Diseases (3) · Glucose Metabolism Disorders (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Cardiovascular Diseases (1) · Coronary Disease (1) · Digestive System Diseases (1) · Fatty Liver (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Heart Diseases (1) · Kidney Diseases (1)
Metformin (2) · Sodium-Glucose Transporter 2 Inhibitors (2) · dapagliflozin (2) · 2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine (1) · Dorzagliatin (1) · Glucagon-Like Peptide 1 (1) · Glycoside Hydrolase Inhibitors (1) · Insulin Glargine (1) · Insulin Lispro (1) · Pioglitazone (1) · Sulfonylurea Compounds (1) · Thiazolidinediones (1) · empagliflozin (1) · henagliflozin (1)
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (1) · Brigham and Women's Hospital (1) · Dong Wha Pharmaceutical Co. Ltd. (1) · First Affiliated Hospital of Guangxi Medical University (1) · Hua Medicine Limited (1) · Jinnah Postgraduate Medical Centre (1) · Medanta, The Medicity, India (1) · University Hospital Tuebingen (1)
China (2) · Bangladesh (1) · Germany (1) · India (1) · Pakistan (1) · South Korea (1) · United States (1)
Faria Afsana, MD (1)
PMID 31912605, PMID 37380728, PMID 39395826, PMID 41456635, PMID 41853855